Recent News

• 05.21.2026 - Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease
• 05.07.2026 - Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights
• 04.03.2026 - Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN)
• 03.25.2026 - Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)

Recent Filings

• 05.22.2026 - 8-K Current report
• 05.22.2026 - EX-99.1 EX-99.1
• 05.15.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 05.07.2026 - EX-99.1 EX-99.1
• 05.07.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.07.2026 - 8-K Current report
• 05.06.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 04.21.2026 - ARS Annual Report to Security Holders
• 04.21.2026 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.21.2026 - DEF 14A Other definitive proxy statements